Olympus Introduces Innovative Single-Use Fine Needle Biopsy for GI Applications

Published: 08 Oct 2025

Author: Precedence Research

Share :

Olympus Corporation, a leading MedTech company focused on enhancing patient outcomes and delivering minimally invasive care. They have introduced the next-generation single-use fine needle biopsy (FNB) device, SecureFlex. The product is capable of enhancing diagnostic accuracy in the process of endoscopic ultrasound-guided fine needle biopsy (EUS-FNB), which is used in the diagnosis of gastrointestinal and pancreatic diseases. SecureFlex is a product developed with substantial input from medical specialists and is a key indicator of Olympus' approach to clinical excellence and technological development in the area of gastrointestinal oncology.

The device is designed to work in conjunction with the ultrasound endoscope to sample submucosal and extramural lesions that are otherwise inaccessible, providing high-quality samples. It is mostly used in the diagnosis and staging of pancreatic cancer, a disease that is currently one of the most aggressive and the most difficult to diagnose at an early stage. SecureFlex is designed to enable clinicians to obtain more accurate tissue samples, thanks to its innovative design and high precision, which enhances both treatment decisions and patient outcomes.

EUS-FNB (Endoscopic Ultrasound-Guided Fine Needle Biopsy) is a key diagnostic methodology that involves the integration of real-time ultrasound imaging. Endoscopic directions to get cellular or tissue specimens of deep-seated organs, including, but not restricted to, the pancreas, lymph nodes, and gastrointestinal wall. In the process, an ultrasound endoscope is passed through the mouth to the target site, and the needle is inserted through the intestinal wall under visualisation using the ultrasound. Afterwards, the samples obtained are tested by pathologists to establish whether the characteristics of the lesion are benign or malignant.

SecureFlex was another dimension that enabled Olympus to be the leader in endoscopic and minimally invasive technologies. It highlights the company's mission to provide healthcare providers with the means to achieve the same high-quality results in terms of consistency and patient safety. It is also anticipated that the gadget will play a central role in facilitating personalized medicine strategies, especially in the field of oncology, where accurate diagnosis will directly inform treatment decisions. Furthermore, with the current growth of Olympus' diagnostics and therapeutic portfolio, the second milestone in the company's quest for excellence in gastrointestinal healthcare solutions is SecureFlex.